Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.
作者信息
Grant Steven
机构信息
Department of Medicine, Division of Hematology/Oncology, Virginia Commonwealth University Health Sciences Center/Massey Cancer Center, Richmond, VA, USA.
出版信息
Leuk Lymphoma. 2011 Sep;52(9):1623-5. doi: 10.3109/10428194.2011.573890.
Abstract
摘要
相似文献
1
Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.用组蛋白去乙酰化酶抑制剂治疗华氏巨球蛋白血症
Leuk Lymphoma. 2011 Sep;52(9):1623-5. doi: 10.3109/10428194.2011.573890.
2
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.伏立诺他诱导的细胞应激破坏了 p38 有丝分裂原激活的蛋白激酶和细胞外信号调节激酶通路，导致沃尔登斯特伦巨球蛋白血症细胞凋亡。
Leuk Lymphoma. 2011 Sep;52(9):1777-86. doi: 10.3109/10428194.2011.577850. Epub 2011 Jun 10.
3
Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation.伏立诺他，一种组蛋白去乙酰化酶抑制剂，通过抑制 iNOS 和 MMP 的表达、p38 和 ERK 的磷酸化以及阻断 NF-κB 核易位，显示出抗骨关节炎活性。
Int Immunopharmacol. 2013 Oct;17(2):329-35. doi: 10.1016/j.intimp.2013.06.027. Epub 2013 Jul 13.
4
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.组蛋白去乙酰化酶抑制对人恶性B细胞的分子后遗症
Blood. 2003 May 15;101(10):4055-62. doi: 10.1182/blood-2002-11-3514. Epub 2003 Jan 16.
5
Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells.p38 MAPK 对依托泊苷诱导 MDA-MB-231 人乳腺癌细胞死亡途径的需求。
Cancer Lett. 2012 Feb 28;315(2):112-21. doi: 10.1016/j.canlet.2011.07.032. Epub 2011 Aug 16.
6
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.卡非佐米在体外和体内与组蛋白去乙酰化酶抑制剂协同作用于套细胞淋巴瘤细胞。
Mol Cancer Ther. 2011 Sep;10(9):1686-97. doi: 10.1158/1535-7163.MCT-10-1108. Epub 2011 Jul 12.
7
Serine proteases in histone deacetylase inhibitor-induced apoptosis.组蛋白去乙酰化酶抑制剂诱导凋亡中的丝氨酸蛋白酶
Mol Cancer Ther. 2010 Aug;9(8):2440-1; author reply 2441-2. doi: 10.1158/1535-7163.MCT-09-0512. Epub 2010 Aug 3.
8
The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways.组蛋白去乙酰化酶抑制剂伏立诺他通过调节多条信号通路来预防 TNFα 诱导的坏死性凋亡。
Apoptosis. 2013 Nov;18(11):1348-1362. doi: 10.1007/s10495-013-0866-y.
9
Different effects of histone deacetylase inhibitors nicotinamide and trichostatin A (TSA) in C17.2 neural stem cells.组蛋白去乙酰化酶抑制剂烟酰胺和 Trichostatin A（TSA）在 C17.2 神经干细胞中的不同作用。
J Neural Transm (Vienna). 2012 Nov;119(11):1307-15. doi: 10.1007/s00702-012-0786-y. Epub 2012 Mar 13.
10
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.伏立诺他是一种组蛋白去乙酰化酶（HDAC）抑制剂，可促进细胞周期停滞，并使利妥昔单抗和化疗耐药的淋巴瘤细胞对化疗药物重新敏感。
J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.
引用本文的文献
1
Novel treatment options for Waldenström macroglobulinemia.华氏巨球蛋白血症的新型治疗选择。
Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2(0 2):S310-6. doi: 10.1016/j.clml.2013.05.023.
本文引用的文献
1
Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.华氏巨球蛋白血症。对其临床、生化、免疫和治疗特征的概述，以及我们在一个中心收集的 121 例患者的系列研究。
Crit Rev Oncol Hematol. 2011 Oct;80(1):87-99. doi: 10.1016/j.critrevonc.2010.09.007. Epub 2010 Oct 29.
2
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.CAAT/增强子结合蛋白同源蛋白在帕比司他增强硼替佐米诱导套细胞淋巴瘤细胞致死性内质网应激中的作用。
Clin Cancer Res. 2010 Oct 1;16(19):4742-54. doi: 10.1158/1078-0432.CCR-10-0529. Epub 2010 Jul 20.
3
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.新型去乙酰化酶抑制剂 AR-42 在体外和体内的 B 细胞恶性肿瘤中显示出临床前活性。
PLoS One. 2010 Jun 3;5(6):e10941. doi: 10.1371/journal.pone.0010941.
4
Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.组蛋白去乙酰化酶抑制剂通过 ATM/NEMO 相关途径激活人白血病细胞中的 NF-κB。
J Biol Chem. 2010 Mar 26;285(13):10064-10077. doi: 10.1074/jbc.M109.095208. Epub 2010 Jan 11.
5
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.全基因组功能丧失筛选揭示了蛋白酶体在组蛋白去乙酰化酶抑制剂诱导的细胞凋亡中的重要作用。
Cancer Cell. 2009 Jan 6;15(1):57-66. doi: 10.1016/j.ccr.2008.12.001.
6
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.硼替佐米与罗米地辛及贝利司他在慢性淋巴细胞白血病细胞中的相互作用。
Clin Cancer Res. 2008 Jan 15;14(2):549-58. doi: 10.1158/1078-0432.CCR-07-1934.
7
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.硼替佐米用于复发/难治性华氏巨球蛋白血症的多中心临床试验：WMCTG试验03 - 248的结果
Clin Cancer Res. 2007 Jun 1;13(11):3320-5. doi: 10.1158/1078-0432.CCR-06-2511.
8
Vorinostat.伏立诺他
Nat Rev Drug Discov. 2007 Jan;6(1):21-2. doi: 10.1038/nrd2227.
9
Small-molecule inhibitors of Bcl-2.
Curr Opin Investig Drugs. 2006 Dec;7(12):1077-84.
10
Anticancer activities of histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂的抗癌活性。
Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133.
Zotero 插件